GLP-1s: Tirzepatide and Retatrutide: Why Adding Peptides Tesamorelin, Ipamorelin, BPC or exercise mimetics (MOTS-c & SLU-PP-332) Preserves Lean Muscle Mass

Tirzepatide: Dual Incretin Physiology

Tirzepatide activates two receptors:

GLP-1 (glucagon-like peptide-1) GIP (glucose-dependent insulinotropic polypeptide)

GLP-1 is released naturally from the gut after you eat. It signals the brain’s hypothalamus to reduce appetite, slows gastric emptying, improves insulin secretion, and reduces glucagon output. The result is improved glycemic control and reduced caloric intake.

GIP enhances insulin secretion in a glucose-dependent manner and may improve adipocyte function and lipid metabolism.

In the SURMOUNT-1 trial published in the New England Journal of Medicine, participants experienced up to 22.5 percent body weight reduction. The authors described “substantial and sustained reductions in body weight.”

Mechanistically, tirzepatide primarily works by lowering energy intake through appetite regulation and improving insulin sensitivity.

Retatrutide: Adding a Third Lever

Retatrutide activates three receptors:

GLP-1 | GIP | Glucagon

That third receptor is what differentiates it.

Glucagon increases energy expenditure, promotes lipolysis, and enhances hepatic fat oxidation. When paired with GLP-1 appetite suppression, glucagon receptor activation may increase total daily energy expenditure while maintaining satiety.

In a 2023 phase 2 trial in the New England Journal of Medicine, retatrutide produced up to 24 percent weight loss at 48 weeks. Investigators noted “robust reductions in body weight across dose levels.”

Physiologically, retatrutide influences both sides of the energy equation:

• Decreased caloric intake

• Increased fat oxidation

• Increased resting energy expenditure

• Improved insulin sensitivity

So while tirzepatide largely reduces intake, retatrutide may reduce intake and increase metabolic output.

The Muscle Preservation Question

One major concern with rapid weight loss is lean mass reduction. Muscle drives basal metabolic rate, insulin sensitivity, and long-term metabolic resilience. Preserving it matters.

This is where growth hormone–modulating peptides enter the picture.

Tesamorelin

Tesamorelin is a growth hormone releasing hormone analog that stimulates pulsatile growth hormone release and increases IGF-1 levels.

In studies published in JAMA, tesamorelin significantly reduced visceral adipose tissue.

Visceral fat is metabolically active and strongly associated with cardiometabolic risk.

Growth hormone preferentially mobilizes visceral fat while helping preserve lean mass.

Ipamorelin

Ipamorelin is a selective ghrelin receptor agonist that stimulates physiologic growth hormone pulses without excessive cortisol or prolactin elevation. It supports recovery, fat mobilization, and muscle preservation during caloric restriction.

The Tesamorelin + Ipamorelin Blend

When combined, tesamorelin and ipamorelin create a dual pathway stimulation of endogenous growth hormone release.

Tesamorelin stimulates the growth hormone releasing hormone receptor at the pituitary. Ipamorelin stimulates the ghrelin receptor pathway.

Together:

• Enhance pulsatile growth hormone amplitude

• Increase IGF-1 within physiologic range

• Target visceral and abdominal fat

• Support lean mass preservation

• Improve recovery during calorie deficit

This combination can be especially useful alongside GLP-1 therapy. As appetite decreases and calories drop, the growth hormone axis can help shift fuel utilization toward adipose tissue while protecting skeletal muscle.

Ipamorelin can also be combined with CJC-1295 to extend growth hormone–releasing hormone signaling, creating a longer duration anabolic and lipolytic signal.

Emerging Metabolic Enhancers

Compounds such as SLU-PP-332 and MOTS-c are being studied as exercise mimetics. Early research suggests they activate mitochondrial oxidative pathways and improve metabolic flexibility. While still investigational, they represent a future layer in metabolic optimization.

BPC-157 is commonly used for tissue support and recovering/healing. Some research suggests it may influence local growth hormone receptor expression in injured tissue, potentially enhancing repair while training during fat loss.

The Strategic Stack = The Answer?

GLP-1 or triple agonist foundation for appetite and metabolic control. Tesamorelin plus ipamorelin blend for visceral fat targeting and lean mass preservation. Resistance training and adequate protein intake. Recovery support when needed.

Weight loss changes the scale.

Preserved muscle, reduced visceral fat, and optimized metabolism change physiology for the long term.